AbbVie Acquires Allergan

Global biopharmaceutical company AbbVie has completed its acquisition of Allergan. The acquisition significantly expands and diversifies AbbVie’s product portfolio, which currently includes Humira, Skyrizi and Rinvoq under its Immunology umbrella, and Hematologic Oncology brands Imbruvica and Venclexta.

AbbVie Prepares for Allergan Acquisition with New Leadership Team

Abbvie Executive Leadership Team

Upon completion of its acquisition of Allergan, AbbVie will create a new global business, called Allergan Aesthetics. Allergan Aesthetics will have its own research and development function under the AbbVie umbrella and will include leading aesthetic products including, BOTOX Cosmetic, the JUVEDERM collection of dermal fillers and COOLSCULPTING body contouring, among others. Located in Irvine, California, the new company will be led by Carrie Strom, current senior vice president, U.S. Medical Aesthetics, Allergan.

AbbVie to Acquire Allergan

AbbVie and Allergan have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction with an equity value of approximately $63 billion. Once the acquisiton is completed, AbbVie will continue maintain its principal executive offices in North Chicago under the leadership of current chairman and CEO Richard A. Gonzalez. Two members of Allergan’s board of directors, including chairman and CEO Brent Saunders, will join AbbVie’s board.

HUMIRA Receives Orphan Drug Designation for HS

HUMIRA Receives Orphan Drug Designation for HS

The U.S. Food and Drug Administration (FDA) granted HUMIRA (adalimumab, AbbVie) orphan drug designation for the investigational treatment of moderate to severe hidradenitis suppurativa (HS)—a painful skin disease for which there is no known cure nor approved medication.

AbbVie's supplemental Biologic License Application seeking FDA approval for the use of HUMIRA for HS is currently under review.